Aclaris Therapeutics Inc (NASDAQ: ACRS) is 177.62% higher on its value in year-to-date trading and has touched a low of $0.86 and a high of $5.17 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACRS stock was last observed hovering at around $2.90 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $2.91, the stock is -14.68% and 5.14% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.76 million and changing 0.52% at the moment leaves the stock 83.15% off its SMA200. ACRS registered 177.62% gain for a year compared to 6-month gain of 162.61%. The firm has a 50-day simple moving average (SMA 50) of $2.7377 and a 200-day simple moving average (SMA200) of $1.583075.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -26.94% loss in the last 1 month and extending the period to 3 months gives it a 147.03%, and is -5.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.31% over the week and 8.93% over the month.
Aclaris Therapeutics Inc (ACRS) has around 91 employees, a market worth around $208.22M and $27.08M in sales. Profit margin for the company is -136.65%. Distance from 52-week low is 240.74% and -43.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.95%).
The EPS is expected to grow by 35.83% this year
107.0 institutions hold shares in Aclaris Therapeutics Inc (ACRS), with institutional investors hold 93.63% of the company’s shares. The shares outstanding are 71.42M, and float is at 59.91M with Short Float at 5.28%. Institutions hold 90.21% of the Float.
The top institutional shareholder in the company is BML CAPITAL MANAGEMENT, LLC with over 12.99 million shares valued at $14.29 million. The investor’s holdings represent 18.2739 of the ACRS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 4.69 million shares valued at $5.16 million to account for 6.5952 of the shares outstanding. The other top investors are MILLENNIUM MANAGEMENT LLC which holds 3.34 million shares representing 4.6948 and valued at over $3.67 million, while D. E. SHAW & CO., INC. holds 4.6714 of the shares totaling 3.32 million with a market value of $3.65 million.
Aclaris Therapeutics Inc (ACRS) Insider Activity
The most recent transaction is an insider purchase by Mehra Anand, the company’s Director. SEC filings show that Mehra Anand bought 666,666 shares of the company’s common stock on Nov 19 ’24 at a price of $2.25 per share for a total of $1.5 million. Following the purchase, the insider now owns 0.71 million shares.
Aclaris Therapeutics Inc disclosed in a document filed with the SEC on Aug 05 ’24 that Leonard Braden Michael (10% Owner) bought a total of 206,025 shares of the company’s common stock. The trade occurred on Aug 05 ’24 and was made at $1.24 per share for $0.26 million. Following the transaction, the insider now directly holds 14.25 million shares of the ACRS stock.
Still, SEC filings show that on Aug 02 ’24, Leonard Braden Michael (10% Owner) acquired 167,544 shares at an average price of $1.29 for $0.22 million. The insider now directly holds 14,043,975 shares of Aclaris Therapeutics Inc (ACRS).
